1. Home
  2. ATNM vs JFU Comparison

ATNM vs JFU Comparison

Compare ATNM & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$0.97

Market Cap

37.1M

Sector

Health Care

ML Signal

SELL

Logo 9F Inc.

JFU

9F Inc.

SELL

Current Price

$2.72

Market Cap

29.9M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ATNM
JFU
Founded
2000
2006
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
37.1M
29.9M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
ATNM
JFU
Price
$0.97
$2.72
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $3.60
N/A
AVG Volume (30 Days)
★ 98.9K
2.8K
Earning Date
11-13-2026
12-09-2022
Dividend Yield
N/A
N/A
EPS Growth
★ 14.17
N/A
EPS
★ 0.71
N/A
Revenue
★ $90,000.00
N/A
Revenue This Year
$19,344.45
$4,000.66
Revenue Next Year
N/A
$5.00
P/E Ratio
★ $1.41
$1.43
Revenue Growth
★ 11.11
N/A
52 Week Low
$0.74
$1.98
52 Week High
$1.74
$9.48

Technical Indicators

Market Signals
Indicator
ATNM
JFU
Relative Strength Index (RSI) 34.56 52.06
Support Level $0.88 $2.40
Resistance Level $1.13 $2.90
Average True Range (ATR) 0.07 0.14
MACD -0.03 0.01
Stochastic Oscillator 1.27 47.81

Price Performance

Historical Comparison
ATNM
JFU

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

Share on Social Networks: